DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This communication is in response to the amendment received on 09/08/2026. Claims 1-26 remain pending in this application.
The objection to claim 24 has been withdrawn in light of the amendment made to this claim.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1-26 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more.
Step 1:
Claims 1-14 and 23-25 are drawn to a system which is within the four statutory categories (i.e. machine). Claims 15-22, 26 are drawn to a method which is within the four statutory categories (i.e. process).
Step 2A, Prong 1:
The independent claims recite:
“…determine an actual bolus fraction of a total daily insulin that was delivered as a total daily bolus dose; determine a ratio of the actual bolus fraction relative to a target bolus fraction; and based at least partially on the determined ratio of the actual bolus fraction relative to a target bolus fraction, determine at least one new value of a parameter…”-claim 1,
“determining an actual amount of a total daily insulin that was delivered as bolus doses; determining a ratio of the actual amount relative to a target amount; and based at least partially on the determined ratio, determining at least one new value of a parameter to utilize in calculating bolus doses”-claim 15,
“…determine insulin deviations made by the automated medicament delivery device subsequent to administration of bolus dose during postprandial periods throughout a given period of time; and based at least partially on the determined insulin deviations, determine at least one new value of a parameter to utilize in determining bolus doses”-claim 23.
These limitations recite mathematical calculations, therefore the limitation falls within the “mathematical concept” grouping of abstract ideas.
These limitations also correspond to “mental processes”, since the claims steps can be done in human mind (or a user using pen and paper) with a recitation of generic computing devices, such as a processor and an automated medicament delivery device. The current specification describes these components as generic computing components, such as in [0134], the current specification recites “The various illustrative methods, logical blocks, modules, and circuits described in connection with the examples of the system 100, and in particular, the automated medicament delivery device 114 and the handheld electronic computing device 138, disclosed herein may be implemented or performed with a general purpose processor, a special purpose processor, a digital signal processor (DSP), an Integrated Circuit (IC), an Application Specific Integrated Circuit (ASIC), a Field Programmable Gate Array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein…”.
Dependent claims 8, 9 and 12 recite mathematical equations, and MPEP recites “A claim that recites a numerical formula or equation will be considered as falling within the "mathematical concepts" grouping.” in section 2106.04(a)(2). Therefore claims 8, 9 and 12 recite an abstract idea.
Claim 4 recites “…provide a recommendation to change at least one previously utilized value of the parameter to the at least one new value of the parameter; and responsive to a user input, change the at least one previously utilized value of the parameter to the at least one new value of the parameter”, claim 18 recites “…providing a recommendation to change at least one previously utilized value of the parameter to the at least one new value of the parameter; and responsive to a user input, changing the at least one previously utilized value of the parameter to the at least one new value of the parameter”, claim 19 recites “…based at least partially on the determined at least one new value of the parameter, generating a request to deliver a bolus dose to a user” and these limitations recite an abstract idea of “certain methods of organizing human activity”. This is a method of managing interactions between people, such as user following rules and instructions.
Claim 6 recites “…comprising instructions that, when executed by the at least one processor, cause the automated medicament delivery device to deliver the bolus dose responsive to the generated request” and claim 20 recites “…responsive to the generated request, delivering the bolus dose”, which corresponds to “insignificant application” (see MPEP 2106.05 (g)).
Claims 2-14, 16-22 and 24-26 are ultimately dependent from claims 1, 15, 23 and include all the limitations of claims 1, 15, 23. Therefore, claims 2-14, 16-22 and 24-26 recite the same abstract idea. Claims 2-14, 16-22 and 24-26 describe a further limitation regarding the basis for determining bolus fractions and new parameters for the medicament delivery. These are all just further describing the abstract idea recited in 1, 15, 23, without adding significantly more.
After considering all claim elements, both individually and in combination and in ordered combination, it has been determined that the claims do not amount to significantly more than the abstract idea itself.
Step 2A, Prong 2:
This judicial exception is not integrated into a practical application. In particular, claims recite the additional elements of “at least one processor; and at least one non-transitory computer-readable storage medium storing instructions thereon that, when executed by the at least one processor, cause the automated medicament delivery device to:…” the determining steps-claim 1, “cause the automated medicament delivery device to automatically change at least one previously utilized value of the parameter to the at least one new value of the parameter without user input”-claim 3, “cause the automated medicament delivery device to generate a request to deliver a bolus dose to the user based at least partially on the at least one new value of the parameter”-claim 5, “cause the automated medicament delivery device to adjust the at least one new value of the parameter based at least partially on a selected rate of adaptation prior to providing a recommendation to change at least one previous utilized value of the parameter to the at least one new value of the parameter”-claim 10, “automatically changing at least one previously utilized value of the parameter to the at least one new value of the parameter without user input”-claim 17, which are hardware and software elements, these limitations are not enough to qualify as “practical application” being recited in the claims along with the abstract idea since these elements are merely invoked as a tool to apply instructions of the abstract idea in a particular technological environment, and mere instructions to apply/implement/automate an abstract idea in a particular technological environment and merely limiting the use of an abstract idea to a particular field or technological environment do not provide practical application for an abstract idea (MPEP 2106.05(f) & (h)).
Claims 1 and 23 have been amended to recite “an analyte sensor configured to obtain analyte data related to one or more analytes within the user-body”. The analyte sensor is described in the current specification as a generic patient monitoring device, such as the current specification recites “The analyte sensor 102 may be configured to obtain data related to one or more analytes within the user-body (“analyte data”). In various examples, the analyte data may include one or more analyte values. In various examples, the analyte sensor 102 is an analytical bio-sensing device, such as a continuous glucose monitor (CGM) or an integrated continuous glucose monitor (iCGM) (e.g., examples of commercially available analytical bio-sensing devices include the FREESTYLE LIBRE® 3 manufactured by Abbott or the DEXCOM® G6 manufactured by Dexcom, without limitation).” in [0037]. Therefore, the analyte sensor corresponds to a generic device and analyte device obtaining analyte data within the user body corresponds to “a well-understood, routine and conventional activity” in the field, as indicated on the current specification.
Claims also recite other additional limitations beyond abstract idea, including functions such as “cause the automated medicament delivery device to deliver the bolus dose responsive to the generated request”-claims 6, “responsive to the generated request, delivering the bolus dose”-claim 20, and these limitations are “insignificant application”, since these limitations impose meaningful limits on the claims such that they are not nominally or tangentially related to the invention (see MPEP 2106.05 (g)), which do not provide a practical application for the abstract idea.
Accordingly, these additional elements do not integrate the abstract idea into a practical application because they do not impose any meaningful limits on practicing the abstract idea. The claims are directed to an abstract idea.
Step 2B:
The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception. As discussed above with respect to integration of the abstract idea into a practical application, the additional element of using a processor to perform determining and automatically changing a value of the parameter within the automated delivery system steps amounts to no more than mere instructions to apply the exception using a generic computer component. Mere instructions to apply an exception using a generic computer component cannot provide an inventive concept.
The claims are not patent eligible.
Response to Arguments
Applicant's arguments filed 09/08/2026 have been fully considered. Applicant’s arguments will be addressed in the order in which they appear.
Arguments about 35 USC 101 rejection:
Applicant argues that claims integrate the recited determinations into a practical application because the determinations configure how an automated medicament delivery device determines bolus doses administered to a user-body.
In response, examiner submits that the claim limitations of “…determine an actual bolus fraction of a total daily insulin that was delivered as a total daily bolus dose; determine a ratio of the actual bolus fraction relative to a target bolus fraction; and based at least partially on the determined ratio of the actual bolus fraction relative to a target bolus fraction, determine at least one new value of a parameter…” correspond to mathematical calculations, which falls within the “mathematical concept” grouping of abstract ideas. Applicant argues that adjusting the parameters and "bringing the user's actual bolus patterns into alignment with assumptions of a control algorithm" may improve the effectiveness of the control algorithm and the automated medicament delivery device "in managing blood glucose levels of users" (specification; [0121]), an improvement in how an automated medicament delivery device manages a user's blood glucose is an improvement in the operation of the device itself. In response, Examiner submits that adjusting the parameters based on a ratio of actual bolus fraction may improve the outcomes of the determination of the parameters, however, it does not improve the technology.
Therefore, the arguments are not persuasive and claims are rejected under 35 U.S.C. §101 as being directed to non-statutory subject matter.
Arguments about 35 USC 102 rejection:
Applicant’s arguments, see Remarks, filed 09/08/2026, with respect to 35 USC 102 rejection of the claims have been fully considered and are persuasive. The rejection has been withdrawn.
Conclusion
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DILEK B COBANOGLU whose telephone number is (571)272-8295. The examiner can normally be reached 8:30-5:00 ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Obeid Mamon can be reached at (571) 270-1813. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/DILEK B COBANOGLU/Primary Examiner, Art Unit 3687